Leukemia & lymphoma · 2020
Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hazar Volkan, Karasu Gülsün Tezcan, Uygun Vedat, Özbek Namık, Karakükçü Musa, Öztürk Gülyüz, Daloğlu Hayriye, Kılıç Suar Çakı, Aksu Tekin, Ünal Ekrem, Koçak Ülker, Yeşilipek Akif, Akçay Arzu, Gürsel Orhan, Küpesiz Alphan, Okur Fatma Visal, İleri Talia, Kansoy Savaş, Bayram İbrahim, Karagün Barbaros Şahin, Gökçe Müge, Kaya Zühre, Ok Bozkaya İkbal, Patıroğlu Türkan, Aksoylar Serap
Аннотация
We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.